Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05767008 |
| Other study ID # |
43-692 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
September 1, 2021 |
| Est. completion date |
April 1, 2022 |
Study information
| Verified date |
March 2023 |
| Source |
Nanometics (d.b.a. PHD Biosciences) |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
This study is designed to determine the Sun Protection Factor (SPF) of a test product
following 80 Minute Water Immersion methodology defined in Final Monograph - Code of Federal
Regulations Title 21 - "Labeling and Effectiveness Testing; Sunscreen Drug Products; Required
Labeling Based on Effectiveness Testing", Final Rule, 21 CFR 201.327.(j)
Description:
All studies will be carried out in a blind fashion according to FDA guidelines, which
describes the number of subjects required to satisfy FDA guidelines and labeling requirements
of sunscreens. Human subject selection: Healthy volunteers (n=25) free from systemic or
dermatological disorders of Fitzpatrick skin type I, II or III (12 male and 13 female; ages
18 through 55) will be recruited. Rectangular test sites of (30 cm2) on the infrascapular
area of the back will be delineated, and inspected to ensure uniform pigmentation, skin tone
and texture, and absence of warts, moles, nevi, scars, blemishes and active dermal lesions.
SPF determination: A 150 W Xenon Arc Solar Simulator, which produces a continuous UV spectra
substantially equivalent to that of natural sunlight will be used and UVB radiation monitored
continuously. Measurements will be recorded within 8 mm from the surface of the skin, and the
size of the exposure site will be ≥ 0.5 cm2. The Sunscreen or a positive control (8%
homosalate) will be applied to subjects evenly in the delineated areas at 2 mg/cm2. Following
static exposures, test sample and water resistant controls will be applied on adjacent sites
for testing. An unprotected site will receive a series of five UV exposures based upon the
previously determined Minimal Erythemal Dose (MED). The UV exposures for each formulation,
will be calculated from previously determined MED and the intended SPF. Immersion procedure:
Immersion will be conducted in a whirlpool tub with room temperature water circulating at
3450 r.p.m. Following pre-immersion SPF measurements, volunteers will be subjected to 80 min
of whirlpool immersion, with SPF measurements taken after air drying at 20, 40, and 80, min.
c. Data Analysis and Interpretation: The 80 min time point is chosen as a benchmark for
success because the FDA only permits finished sunscreen products to be labeled as water
resistant for up to 80 min. All subjects will return to the laboratory sixteen to twenty-four
hours post-exposure for a blinded determination of erythema responses, the mean SPF, standard
deviation (s) value, and standard error (SE). No attempts to determine the influence of sex
or age on the interpretation of results will be undertaken because of Phase I SBIR budgetary
and time limitations, and because this is not a requirement of FDA or customers /
distribution partners who will purchase the product. The standard deviation (s) will be
determined and the upper 5% point was obtained from the t distribution table with n-1 degrees
of freedom (t).
